Πέμπτη 22 Νοεμβρίου 2018

Final Episode (or Not)

I do not particularly enjoy farewells. Speeches. Letters. Parties. Even writing a "my time is over" editorial, like this one. Which probably explains why I am so fascinated by the topic of space. Space just never seems to end and that captures my imagination. You know, "Space, The Final Frontier. These are the voyages of the Starship Enterprise…etc., etc." I have to admit that I still watch on Netflix the re-run adventures of iconic Starship Captains Kirk, Picard, Sisko, Janeway, (and even Archer).

from Rehabilitation via xlomafota13 on Inoreader https://ift.tt/2S77aBQ
via IFTTT

Message from the Editor-in-Chief

This is a historic moment for PM&R. Volume 10, issue 12, wraps up our first decade of existence. In so many ways, PM&R has been a great success story: obtaining Index Medicus status at 6 months, first Impact Factor (IF) at year 4, highest IF to date in 2018 (1.850), steady increase in manuscript submissions, maintaining a healthy rejection rate, and providing unique and relevant article types simply not found in our competitor's journals.

from Rehabilitation via xlomafota13 on Inoreader https://ift.tt/2DWvqDU
via IFTTT

Dealing With Binary Repeated Measures Data

Many longitudinal studies and randomized trials have binary outcomes that can repeat. For example, in a study evaluating the safety of a new drug, researchers might record whether a subject developed an adverse reaction at multiple time points during follow-up. These observations are correlated and thus require statistical tests that handle correlated data. Several different statistical models can be applied; this article reviews the advantages and disadvantages of each approach.

from Rehabilitation via xlomafota13 on Inoreader https://ift.tt/2S770dI
via IFTTT

The Many Faces of Peroxisomal Disorders: Lessons from A Large Arab Cohort

Clinical Genetics The Many Faces of Peroxisomal Disorders: Lessons from A Large Arab Cohort

Defects in the peroxisomes biogenesis and/or function result in peroxisomal disorders. In this study, we describe the largest Arab cohort to date (72 families) of clinically, biochemically and molecularly characterized patients with peroxisomal disorders. At the molecular level, we identified 43 disease‐causing variants, half of which are novel. The founder nature of many of the variants allowed us to calculate the minimum disease burden for these disorders in our population ~1:30,000, which is much higher than previous estimates in other populations. Clinically, we found an interesting trend towards genotype/phenotype correlation in terms of long‐term survival. Nearly half (40/75) of our peroxisomal disorders patients had documented survival beyond one year of age. Most unusual among the long‐term survivors was a multiplex family in which the affected members presented as adults with nonspecific intellectual disability and epilepsy. Other unusual presentations included the very recently described peroxisomal fatty acyl‐CoA reductase 1 disorder as well as CRSPW syndrome. We conclude that peroxisomal disorders are highly heterogeneous in their clinical presentation. Our data also confirm the demonstration that milder forms of Zellweger spectrum disorders cannot be ruled out by the "gold standard" VLCFA assay, which highlights the value of a genomics‐first approach in these cases.

This article is protected by copyright. All rights reserved.



from Genetics via xlomafota13 on Inoreader https://ift.tt/2zkfwiM
via IFTTT

Genetic Risk Score modifies the effect of APOE on risk and age onset of Alzheimer’s disease

Clinical Genetics Genetic Risk Score modifies the effect of APOE on risk and age onset of Alzheimer's disease

Single nucleotide polymorphism (SNP)‐based genetic risk score (GRS) and APOE genotype are both important in risk prediction of Alzheimer's disease (AD); however, the interaction between GRS and APOE has not been extensively investigated. Our objective was to determine whether GRS modifies the APOE effect on AD risk and age at onset (AAO). The study included 774 AD cases and 767 controls of European descent. Population standardized GRS was calculated based on 17 previously implicated AD risk‐associated SNPs. Association was analyzed using logistic regression, Cox proportional hazards model and Kaplan–Meier curve. We found that GRS was significantly associated with AD risk and the association was stronger among APOE ε4 carriers. Compared to ε4 non‐carriers, the Odds Ratio (OR) for AD was 8.09 (95% Confidence Interval [CI]: 4.98‐13.63) for ε4 carriers with high‐GRS (≥1.5). In contrast, the OR was 2.55 (95% CI: 1.46‐4.49) for ε4 carriers with low‐GRS (<0.6). In conclusion, these results suggest SNP‐based GRS may supplement APOE for better assessment of inherited risk and age of onset of AD.

This article is protected by copyright. All rights reserved.



from Genetics via xlomafota13 on Inoreader https://ift.tt/2OZ2WdR
via IFTTT

A novel mutation in MYORG causes primary familial brain calcification with central neuropathic pain

Clinical Genetics A novel mutation in MYORG causes primary familial brain calcification with central neuropathic pain


from Genetics via xlomafota13 on Inoreader https://ift.tt/2zoDoBU
via IFTTT

A novel nonsense homozygous variant in the NLGN1 gene found in a pair of monozygotic twin brothers with intellectual disability and autism

Clinical Genetics A novel nonsense homozygous variant in the NLGN1 gene found in a pair of monozygotic twin brothers with intellectual disability and autism


from Genetics via xlomafota13 on Inoreader https://ift.tt/2OXyj8E
via IFTTT